Article Text

Multiplexed endoscopic imaging of Barrett’s neoplasia using targeted fluorescent heptapeptides in a phase 1 proof-of-concept study
  1. Jing Chen1,
  2. Yang Jiang2,
  3. Tse-Shao Chang3,
  4. Bishnu Joshi1,
  5. Juan Zhou1,
  6. Joel H Rubenstein1,
  7. Erik J Wamsteker1,
  8. Richard S Kwon1,
  9. Henry Appelman4,
  10. David G Beer5,
  11. Danielle K Turgeon1,
  12. Eric J Seibel6,
  13. Thomas D Wang1,3,7
  1. 1Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
  2. 2Biomedical Engineering, University of Washington, Seattle, WA, USA
  3. 3Mechanical Engineering, University of Michigan, Ann Arbor, Michigan, USA
  4. 4Pathology, University of Michigan, Ann Arbor, Michigan, USA
  5. 5Thoracic Surgery, University of Michigan, Ann Arbor, Michigan, USA
  6. 6Mechanical Engineering, University of Washington, Seattle, WA, USA
  7. 7Biomedical Engineering, University of Michigan, Ann Arbor, MI, USA
  1. Correspondence to Dr Thomas D Wang, Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA; thomaswa{at}

Statistics from


Improved methods for early cancer detection arising from Barrett’s oesophagus (BE) are still needed. Imaging molecular expression patterns in BE patients can target neoplasia. We demonstrate a multiplexed fluorescence imaging approach to detect premalignant lesions with two fluorescently labeled heptapeptides specific for EGFR and ErbB2. Twenty-two BE patients underwent endoscopic imaging with a multimodal scanning fiber endoscope (mmSFE). In this pilot study, 92% of neoplastic lesions could be imaged by comparison with pathology, with only 11% false positives. This first-in-human study demonstrates feasibility to concurrently detect multiple targets in vivo and potential for early detection of cancers that are molecularly heterogeneous.

Iniedmore detail


Oesophageal adenocarcinoma (EAC) is a deadly disease that has increased dramatically in incidence over the past several decades.1 2 Endoscopic screening with white light illumination and random biopsy is limited by sampling error.3 Dysplasia often presents with flat architecture and patchy distribution.4 EGFR and ErbB2 are transmembrane tyrosine kinase receptors that stimulate epithelial cell growth, proliferation and differentiation.5 Overexpression of these targets reflects a higher risk for cancer progression.6–8 Multiplexed imaging methods take advantage of the broad spectrum of light over the visible and near-infrared (NIR) regimen. We aim to demonstrate clinical feasibility to visualise EGFR and ErbB2 expression simultaneously in vivo to detect Barrett’s neoplasia.


Consecutive patients referred for either evaluation or therapy of Barrett’s neoplasia were recruited for the study (NCT03589443). An mmSFE was designed to collect multiplexed fluorescence images concurrently. Target/background (T/B) ratios were calculated for each fluorescence image. More details on the methods and the multiplexed imaging technology can be found in the online supplemental file.

Supplemental material


The peptide QRHKPRE specific for EGFR was labelled with Cy5 via a GGGSK linker, (figure 1A).9 KSPNPRF, specific for ErbB2, was labelled with IRDye800 via a GGGSC linker (figure 1B).10 These fluorophores were chosen to minimise overlap between absorbance and emission spectra (figure 1C). The characteristics and stability of fluorescently labelled peptides are shown in online supplemental tables S1–S4. The pharmacology/toxicology study shows no acute adverse effects in animals (online supplemental tables S5 and S6). The phase 1 safety study was performed in n=25 human, and no abnormalities were identified in the laboratory results, urinalysis and ECG for either peptide, and no adverse events were found.

Figure 1

Fluorescently labelled peptides for multiplexed imaging. Biochemical structures are shown for (A) QRH*-Cy5 and (B) KSP*-IRDye800. (C) Peak absorbance of QRH*-Cy5 and KSP*-IRDye800 occurs at abs=648 and 776 nm, respectively. Peak fluorescence emits at em=675 and 812 nm, respectively. (D) Schematic diagram for the multimodal scanning fibre endoscope (mmSFE) is shown. Excitation at ex=638 and 785 nm is delivered through a single-mode fibre (SMF) that is scanned in a spiral pattern by a piezo tube actuator. The beam is focused onto the tissue surface (illumination plane) by a lens assembly. (E) Fluorescence is collected by a ring of large core multi-mode fibres (MMF) mounted around the instrument periphery. (F) The dimensions of the rigid tip are 9 mm in length and 2.4 mm in diameter. (G) This instrument passes forward through the 2.7 mm working channel of a standard medical endoscope (Olympus #GIF-HQ190). (H) The system is contained within a portable cart.

The mmSFE was designed to collect multiplexed fluorescence images (figure 1D–H). Contrast agents were administered, and real-time images were collected from n=22 subjects, table 1 (online supplemental videos S1–S23). Representative white light images are shown for squamous (SQ) and non-dysplastic BE (NDBE) (figure 2A,B). Minimal background was seen following peptide administration. Fluorescence images were collected in separate channels, and coregistered reflectance provided anatomic landmarks for image interpretation. A representative set of in vivo images for HGD and EAC is shown (figure 2C,D). Increased fluorescence intensities were seen from regions of HGD and EAC, and were confirmed by pathology. Immunohistochemistry (IHC) was performed to validate expression of EGFR and ErbB2 on excised specimens (online supplemental figure S1).

Table 1

Patient demographics

Figure 2

Barrett’s oesophagus. Representative in vivo images collected endoscopically are shown from patients with (A) squamous (SQ), (B) non-dysplastic Barrett’s oesophagus (NDBE), (C) high-grade dysplasia (HGD) and (D) oesophageal adenocarcinoma (EAC). The presence of NDBE is identified by the salmon red patches (arrows) in the white light images. Fluorescence images are collected after separate topical administration of QRH*-Cy5 and KSP*-IRDye800. The merged images show high contrast regions-of interest (ROI) where EGFR and ErbB2 (orange) are coexpressed. Coregistered reflectance images provide anatomical landmarks to interpret the location of the ROI’s.

The T/B ratios using QRH*-Cy5 and KSP*-IRDye800 were measured from individual patients (figure 3A,B). For SQ (n=2) or NDBE (n=3), a mean (±SD) T/B ratio of 1.28±0.07 for QRH*-Cy5 and 1.33±0.15 for KSP*-IRDye800, respectively, was calculated. The T/B for (n=4) LGD was 1.23±0.05 and 1.18±0.10, respectively. For HGD (n=7) and EAC (n=6), a mean (±SD) T/B ratio of 1.61±0.21 and 1.68±0.24, respectively, was found. Leave-one-out cross-validation (LOOCV) was used to classify results (online supplemental table S7). Support vector machine (SVM) and logistic regression (LR) provided the highest classification accuracy of 91%. The imaging results revealed n=12, 1, 8 and 1 true positives, false positives, true negatives and false negatives, respectively, resulting in 92% sensitivity and 89% specificity. The decision boundaries using SVM and LR are shown. The ROC curves using these methods with LOOCV are displayed (figure 3C). A higher AUC was achieved with multiplexed detection versus either target alone from bootstrap (figure 3D).

Figure 3

In vivo imaging performance. Scatter plot shows target/background (T/B) ratios measured for EGFR and ErbB2 expression in the fluorescence images collected in vivo from the distal oesophagus of n=22 patients. Decision boundaries show regions classified as either negative (blue) or positive (brown) for neoplasia using (A) support vector machine (SVM) and (B) logistic regression (LR) trained on all data. (C) ROC curves for classifying HGD/EAC from SQ/NDBE/LGD are shown using SVM and LR algorithms with leave-one-out cross-validation (LOOCV). (D) Average ROC curves from bootstrap using SVM (AUC=0.97) model trained on all data show that multiplexed detection provides improved performance than using either EGFR (AUC=0.95) or ErbB2 alone (AUC=0.94). AUC, area under curve; EGFR. epithelial growth factor receptor; ErbB2. epithelial growth factor receptor2; ROC, receiver-operator characteristic.


Here, we demonstrate feasibility to detect Barrett’s neoplasia endoscopically by imaging two targets concurrently in vivo. Fluorescently labelled peptides specific for epithelial growth factor receptor (EGFR) and epithelial growth factor receptor2 (ErbB2) were administered topically in the distal oesophagus of n=22 BE patients. With conventional white light illumination, structural abnormalities associated with Barrett’s neoplasia appeared subtle. By comparison, spatial patterns of target expression were visualised with high contrast using fluorescence. Two laser excitation wavelengths were delivered concurrently through a single flexible optical fibre using a prototype-wide-field endoscope accessory. Adequate signal was collected by using large core, high numerical aperture fibres. The regions imaged were compared with histopathology of specimens excised via either endoscopic mucosal resection or biopsy. IHC of these specimens confirmed heterogeneous expression of EGFR and ErbB2.

To our knowledge, this study first demonstrates clinical application of multiplexed fluorescence imaging during endoscopy. Many cancers, including EAC, are molecularly heterogeneous, thus detection of multiple targets is likely to be needed for accurate clinical diagnosis. Mucosal abnormalities with non-specific features, such as nodularity, ulceration and irregularities, may not be relied on to accurately locate Barrett’s neoplasia. Several medical societies recommend random 4-quadrant biopsies for EAC surveillance, but this sampling method is inefficient and has been poorly adopted by community physicians.11 Molecular biomarkers can be highly specific for disease, and are expressed well before neoplastic lesions become grossly apparent. Endoscopic imaging strategies for detecting these targets in vivo can be used to guide and prioritise high risk regions for resection, reduce surveillance frequency, and minimise over diagnosis.

Recently, detection of dysplasia and early EAC in BE patients was demonstrated using an antibody specific for vascular endothelial growth factor A. Bevacizumab was originally developed for cancer therapy, and was repurposed for diagnostic imaging by labelling with IRDye800.12 Compared with antibodies, peptides are smaller in size, have faster binding kinetics, and can be mass manufactured at lower costs.13–15 The peptides were delivered to the mucosal surface in the distal oesophagus using topical administration. This method was effective for staining regions of neoplastic BE involvement.16 Compared with systemic delivery, this approach localises the distribution of exogenous imaging agents to the target tissues only, minimises background and maximises image contrast. This strategy was chosen because the peptides used have similar binding kinetics.9 10 Lectins have been investigated for detection of Barrett’s neoplasia ex vivo,17 but have not been demonstrated clinically. Fluorescently labelled peptides for targeted detection of premalignant lesions in the colon have also been shown clinically.18 19 Folate has been developed for targeted imaging of ovarian cancer,20 however, small molecules have limited flexibility for fluorescence labelling and would be difficult to use with multiplexed imaging.

In this work, light over a broad optical spectrum was collected using a flexible fibre endoscope accessory, and was separated into fluorescence and reflectance channels.21 Multipixel photon counters with much higher sensitivity than the charge-coupled devices found in video endoscopes were used. Multiplexed detection was achieved by exciting Cy5 and IRDye800 at wavelengths with minimal overlap between the absorption and emission bands. Additional targets can be detected by extending this strategy to the full visible and NIR spectrum.22 Fluorescence emission in the NIR regimen mitigates the effects of haemoglobin absorption and tissue scattering, and minimises tissue autofluorescence background.23 The distal optics and scan strategy used provide much greater spatial resolution than an optical fibre bundle.

The clinical usefulness of this technology can be improved by addressing several study limitations. The peptides were administered separately to minimise potential binding interactions but can be combined to reduce time needed to reconstitute and prepare the peptides for delivery. After inserting the imaging accessory through the working channel, the fluorescence and HD-WLE images were not oriented. Accurate alignment would allow the fluorescence images to be more effective as a guide for tissue resection. This study was performed at a tertiary referral centre that specialises in treatment of patients with advanced BE, thus a cohort highly enriched with neoplasia was studied. Inclusion of more non-neoplastic subjects would better reflect the prevalence of disease seen in the community. In conclusion, we demonstrated a proof-of-concept study for detecting multiple targets concurrently in patients with Barrett’s neoplasia and this strategy is promising for early detection of cancers in other hollow organs.


We thank E Brady, D Chandhrasekhar, and A Cawthon for clinical support, and BR Reisdorph for regulatory support.


View Abstract

Supplementary materials


  • Contributors JC, BJ, JZ, DGB, DKT, EJS and TDW conceived and designed the experiments. JC, T-SC, JHR, EJW and RSK performed the experiments. JHR, YJ and EJS contributed to image and data analysis. HA reviewed pathology. JC, YJ, EJS and TDW wrote the manuscript.

  • Funding This study was supported in part by the National Institutes of Health U54 CA163059 (DGB, JHR, EJS, TDW), U01 CA189291 (TDW) and R01 CA200007 (EJS, TDW).

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.